文献速递糖尿病

二甲双胍给药时机对2型糖尿病患者十二指肠内葡萄糖输注后血糖及胰高血糖素样肽-1反应的影响:一项双盲、随机、安慰剂对照、交叉研究

Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.
PubMed 文献 · Diabetologia · 2024-04-01

在16例经二甲双胍单药治疗控制良好的2型糖尿病患者中,采用双盲随机安慰剂对照交叉设计,比较二甲双胍在十二指肠内葡萄糖输注前60分钟、前30分钟或同时(0分钟)给药对血糖、胰岛素和总GLP-1的影响。结果显示,提前60或30分钟给药较同时给药的降糖幅度更大,且仅在提前给药时观察到GLP-1升高。

要点

  • 二甲双胍在葡萄糖输注前60或30分钟给药较同时给药的降糖幅度更大(p<0.05)。
  • 仅在葡萄糖输注前60或30分钟给予二甲双胍时观察到血浆GLP-1水平升高(p<0.05)。
  • 二甲双胍增强葡萄糖刺激的胰岛素分泌(p<0.05),但不影响胰岛素敏感性。

核心结论

  • 在控制良好的二甲双胍治疗的2型糖尿病患者中,肠内葡萄糖输注前给予二甲双胍较同时给药降糖幅度更大,且与更大的GLP-1反应相关。
  • 这些观察提示餐前给予二甲双胍可能优化其改善餐后血糖控制的效果。

研究设计与样本

  • 双盲、随机、安慰剂对照、交叉研究,纳入16例经二甲双胍单药治疗控制良好的2型糖尿病患者,在四个不同研究日接受干预。
  • 每个研究日通过鼻十二指肠导管在t=-60、-30或0分钟给予二甲双胍弹丸输注(1000 mg溶于50 ml 0.9%氯化钠),其他时间点给予生理盐水,或所有时间点均给予生理盐水(对照),随后在t=0-60分钟进行十二指肠内葡萄糖输注(12.56 kJ/min,即3 kcal/min)。
  • 在t=-60分钟至t=120分钟之间每30分钟测量血浆葡萄糖、胰岛素和总GLP-1水平。

主要发现

  • 二甲双胍降低血浆葡萄糖水平以及升高血浆GLP-1和胰岛素水平存在治疗与时间的交互作用(每项p<0.05)。
  • 在t=-60或-30分钟给予二甲双胍时血浆葡萄糖水平降低幅度大于t=0分钟给药(每项p<0.05)。
  • 仅在t=-60或-30分钟给予二甲双胍时观察到血浆GLP-1水平升高(每项p<0.05)。
  • 二甲双胍不影响胰岛素敏感性,但增强葡萄糖刺激的胰岛素分泌(p<0.05);给予二甲双胍的3天中血浆胰岛素水平升高幅度相当。

临床怎么用

  • 作者认为,餐前给予二甲双胍可能优化其改善餐后血糖控制的效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Metformin lowers postprandial glycaemic excursions in individuals with type 2 diabetes by modulating gastrointestinal function, including the stimulation of glucagon-like peptide-1 (GLP-1). The impact of varying the timing of metformin administration on postprandial glucose metabolism is poorly defined. We evaluated the effects of metformin, administered at different intervals before an intraduodenal glucose infusion, on the subsequent glycaemic, insulinaemic and GLP-1 responses in metformin-treated type 2 diabetes. METHODS: Sixteen participants with type 2 diabetes that was relatively well-controlled by metformin monotherapy were studied on four separate days in a crossover design. On each day, participants were randomised to receive a bolus infusion of metformin (1000 mg in 50 ml 0.9% saline) via a nasoduodenal catheter at t = -60, -30 or 0 min (and saline at the other timepoints) or saline at all timepoints (control), followed by an intraduodenal glucose infusion of 12.56 kJ/min (3 kcal/min) at t = 0-60 min. The treatments were blinded to both participants and investigators involved in the study procedures. Plasma glucose, insulin and total GLP-1 levels were measured every 30 min between t = -60 min and t = 120 min. RESULTS: There was a treatment-by-time interaction for metformin in reducing plasma glucose levels and increasing plasma GLP-1 and insulin levels (p<0.05 for each). The reduction in plasma glucose levels was greater when metformin was administered at t = -60 or -30 min vs t = 0 min (p<0.05 for each), and the increases in plasma GLP-1 levels were evident only when metformin was administered at t = -60 or -30 min (p<0.05 for each). Although metformin did not influence insulin sensitivity, it enhanced glucose-induced insulin secretion (p<0.05), and the increases in plasma insulin levels were comparable on the 3 days when metformin was given. CONCLUSIONS/INTERPRETATION: In well-controlled metformin-treated type 2 diabetes, glucose-lowering by metformin is greater when it is given before, rather than with, enteral glucose, and this is associated with a greater GLP-1 response. These observations suggest that administration of metformin before meals may optimise its effect in improving postprandial glycaemic control. TRIAL REGISTRATION: www.anzctr.org.au ACTRN12621000878875 FUNDING: The study was not funded by a specific research grant.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Xie C, Iroga P, Bound MJ, et al. Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study. Diabetologia. 2024. PMID: 38561463. doi:10.1007/s00125-024-06131-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。